메뉴 건너뛰기




Volumn 14, Issue , 2016, Pages 168-175

Phase 2a Randomized Clinical Trial: Safety and Post Hoc Analysis of Subretinal rAAV.sFLT-1 for Wet Age-related Macular Degeneration

Author keywords

AAV.sFLT 1; Clinical trial; Gene therapy; Wet age related macular degeneration

Indexed keywords

GENE THERAPY AGENT; PARVOVIRUS VECTOR; RANIBIZUMAB; SOLUBLE FMS LIKE TYROSINE KINASE 1; UNCLASSIFIED DRUG; VIRUS DNA; FLT1 PROTEIN, HUMAN; VASCULOTROPIN RECEPTOR 1;

EID: 85003977057     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.11.016     Document Type: Article
Times cited : (139)

References (31)
  • 2
    • 0021827230 scopus 로고
    • Long-term diabetic vitrectomy results. Report of 10 year follow-up
    • Blankenship, G.W., Machemer, R., Long-term diabetic vitrectomy results. Report of 10 year follow-up. Ophthalmology 92 (1985), 503–506.
    • (1985) Ophthalmology , vol.92 , pp. 503-506
    • Blankenship, G.W.1    Machemer, R.2
  • 3
    • 0036300131 scopus 로고    scopus 로고
    • PEDF: anti-angiogenic guardian of ocular function
    • Bouck, N., PEDF: anti-angiogenic guardian of ocular function. Trends Mol. Med. 8 (2002), 330–334.
    • (2002) Trends Mol. Med. , vol.8 , pp. 330-334
    • Bouck, N.1
  • 9
    • 36249002808 scopus 로고    scopus 로고
    • Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results
    • Kaiser, P.K., Brown, D.M., Zhang, K., Hudson, H.L., Holz, F.G., Shapiro, H., Schneider, S., Acharya, N.R., Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J. Ophthalmol. 144 (2007), 850–857.
    • (2007) Am J. Ophthalmol. , vol.144 , pp. 850-857
    • Kaiser, P.K.1    Brown, D.M.2    Zhang, K.3    Hudson, H.L.4    Holz, F.G.5    Shapiro, H.6    Schneider, S.7    Acharya, N.R.8
  • 10
    • 0027421333 scopus 로고
    • Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor
    • Kendall, R.L., Thomas, K.A., Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. U. S. A. 90 (1993), 10705–10709.
    • (1993) Proc. Natl. Acad. Sci. U. S. A. , vol.90 , pp. 10705-10709
    • Kendall, R.L.1    Thomas, K.A.2
  • 11
    • 0031050126 scopus 로고    scopus 로고
    • Increased expression of angiogenic growth factors in age-related maculopathy
    • Kliffen, M., Sharma, H.S., Mooy, C.M., Kerkvliet, S., De Jong, P.T., Increased expression of angiogenic growth factors in age-related maculopathy. Br. J. Ophthalmol. 81 (1997), 154–162.
    • (1997) Br. J. Ophthalmol. , vol.81 , pp. 154-162
    • Kliffen, M.1    Sharma, H.S.2    Mooy, C.M.3    Kerkvliet, S.4    De Jong, P.T.5
  • 12
    • 0034919401 scopus 로고    scopus 로고
    • Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization
    • Lai, C.M., Brankov, M., Zaknich, T., Lai, Y.K., Shen, W.Y., Constable, I.J., Kovesdi, I., Rakoczy, P.E., Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum. Gene Ther. 12 (2001), 1299–1310.
    • (2001) Hum. Gene Ther. , vol.12 , pp. 1299-1310
    • Lai, C.M.1    Brankov, M.2    Zaknich, T.3    Lai, Y.K.4    Shen, W.Y.5    Constable, I.J.6    Kovesdi, I.7    Rakoczy, P.E.8
  • 16
    • 0347532850 scopus 로고    scopus 로고
    • Virus-mediated secretion gene therapy – a potential treatment for ocular neovascularization
    • Lai, Y.K., Sharma, S., Lai, C.M., Brankov, M., Constable, I.J., Rakoczy, P.E., Virus-mediated secretion gene therapy – a potential treatment for ocular neovascularization. Adv. Exp. Med. Biol. 533 (2003), 447–453.
    • (2003) Adv. Exp. Med. Biol. , vol.533 , pp. 447-453
    • Lai, Y.K.1    Sharma, S.2    Lai, C.M.3    Brankov, M.4    Constable, I.J.5    Rakoczy, P.E.6
  • 17
    • 0036083592 scopus 로고    scopus 로고
    • Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy
    • Lai, Y.K., Shen, W.Y., Brankov, M., Lai, C.M., Constable, I.J., Rakoczy, P.E., Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Ther. 9 (2002), 804–813.
    • (2002) Gene Ther. , vol.9 , pp. 804-813
    • Lai, Y.K.1    Shen, W.Y.2    Brankov, M.3    Lai, C.M.4    Constable, I.J.5    Rakoczy, P.E.6
  • 18
    • 67149101784 scopus 로고    scopus 로고
    • A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study
    • e1
    • Lalwani, G.A., Rosenfeld, P.J., Fung, A.E., Dubovy, S.R., Michels, S., Feuer, W., Davis, J.L., Flynn, H.W. Jr., Esquiabro, M., A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J. Ophthalmol. 148 (2009), 43–58, e1.
    • (2009) Am J. Ophthalmol. , vol.148 , pp. 43-58
    • Lalwani, G.A.1    Rosenfeld, P.J.2    Fung, A.E.3    Dubovy, S.R.4    Michels, S.5    Feuer, W.6    Davis, J.L.7    Flynn, H.W.8    Esquiabro, M.9
  • 19
    • 54549125880 scopus 로고    scopus 로고
    • Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential
    • Li, Q., Miller, R., Han, P.Y., Pang, J., Dinculescu, A., Chiodo, V., Hauswirth, W.W., Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol. Vis. 14 (2008), 1760–1769.
    • (2008) Mol. Vis. , vol.14 , pp. 1760-1769
    • Li, Q.1    Miller, R.2    Han, P.Y.3    Pang, J.4    Dinculescu, A.5    Chiodo, V.6    Hauswirth, W.W.7
  • 22
    • 84944339068 scopus 로고    scopus 로고
    • Gene therapy returns to centre stage
    • Naldini, L., Gene therapy returns to centre stage. Nature 526 (2015), 351–360.
    • (2015) Nature , vol.526 , pp. 351-360
    • Naldini, L.1
  • 24
    • 84928599756 scopus 로고    scopus 로고
    • The status of RPE65 Gene therapy trials: safety and efficacy
    • Pierce, E.A., Bennett, J., The status of RPE65 Gene therapy trials: safety and efficacy. Cold Spring Harb. Perspect. Med., 5, 2015, a017285.
    • (2015) Cold Spring Harb. Perspect. Med. , vol.5 , pp. a017285
    • Pierce, E.A.1    Bennett, J.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.